
    
      A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and
      Pharmacokinetics of MP-376 Inhalation Solution given Daily for 14 Days to Stable Pediatric
      Cystic Fibrosis Patients.
    
  